Online survey of medicinal cannabis users: Qualitative analysis of patient-level data
- PMID: 36147312
- PMCID: PMC9485457
- DOI: 10.3389/fphar.2022.965535
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data
Abstract
Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users. Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed. Results: Respondents (N = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and/or had intolerable side effects (51%), positive scientific or media portrayals of the safety/efficacy of cannabis as a therapeutic (29%), or preference for "natural" treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%). Conclusion: Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis/cannabinoid use is warranted.
Keywords: CBD-cannabidiol; THC-tetrahydrocannabinol; cannabis (marijuana); medical marijuana; qualitative.
Copyright © 2022 Garcia-Romeu, Elmore, Mayhugh, Schlienz, Martin, Strickland, Bonn-Miller, Jackson and Vandrey.
Conflict of interest statement
AG-R is a scientific advisor to Etha Natural Botanicals, Innerwell, and NeonMind Biosciences. RV has received compensation as a consultant or scientific advisor from MyMD Pharmaceuticals, Mira1a Pharmaceuticals Inc. Canopy Health Innovations, Syqe Medical Ltd. WebMD, and Radicle Science Inc. MB-M is employed by Canopy Growth Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.Cannabis Cannabinoid Res. 2022 Aug;7(4):482-500. doi: 10.1089/can.2020.0129. Epub 2021 Mar 17. Cannabis Cannabinoid Res. 2022. PMID: 33998895 Free PMC article.
-
Self-reported Medicinal Cannabis Use as an Alternative to Prescription and Over-the-counter Medication Use Among US Military Veterans.Clin Ther. 2023 Jun;45(6):562-577. doi: 10.1016/j.clinthera.2023.04.003. Clin Ther. 2023. PMID: 37414507
-
Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont.J Prim Care Community Health. 2020 Jan-Dec;11:2150132720946954. doi: 10.1177/2150132720946954. J Prim Care Community Health. 2020. PMID: 32757826 Free PMC article.
-
Pharmacology of Medical Cannabis.Adv Exp Med Biol. 2019;1162:151-165. doi: 10.1007/978-3-030-21737-2_8. Adv Exp Med Biol. 2019. PMID: 31332738 Review.
-
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.Pharmacology. 2022;107(3-4):131-149. doi: 10.1159/000521683. Epub 2022 Jan 28. Pharmacology. 2022. PMID: 35093949 Review.
Cited by
-
Medicinal and combined medicinal/recreational cannabis use in California following the passage of Proposition 64.J Cannabis Res. 2025 Jul 12;7(1):44. doi: 10.1186/s42238-025-00285-9. J Cannabis Res. 2025. PMID: 40652264 Free PMC article.
-
An Individual's Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety.Int J Environ Res Public Health. 2023 Sep 18;20(18):6776. doi: 10.3390/ijerph20186776. Int J Environ Res Public Health. 2023. PMID: 37754635 Free PMC article.
-
Detecting and understanding potential stigma among medical cannabis users in Germany.BMC Public Health. 2025 Mar 5;25(1):874. doi: 10.1186/s12889-025-22084-w. BMC Public Health. 2025. PMID: 40045288 Free PMC article.
-
Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership.Front Psychiatry. 2023 Mar 7;14:1083334. doi: 10.3389/fpsyt.2023.1083334. eCollection 2023. Front Psychiatry. 2023. PMID: 36960460 Free PMC article.
-
Oral CBD-rich hemp extract modulates sterile inflammation in female and male rats.Front Physiol. 2023 May 18;14:1112906. doi: 10.3389/fphys.2023.1112906. eCollection 2023. Front Physiol. 2023. PMID: 37275221 Free PMC article.
References
LinkOut - more resources
Full Text Sources